These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26278026)

  • 1. Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
    Cheoymang A; Ruenweerayut R; Muhamad P; Rungsihirunrat K; Na-Bangchang K
    Acta Trop; 2015 Dec; 152():151-156. PubMed ID: 26278026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Chu CS; Phyo AP; Turner C; Win HH; Poe NP; Yotyingaphiram W; Thinraow S; Wilairisak P; Raksapraidee R; Carrara VI; Paw MK; Wiladphaingern J; Proux S; Bancone G; Sriprawat K; Lee SJ; Jeeyapant A; Watson J; Tarning J; Imwong M; Nosten F; White NJ
    Clin Infect Dis; 2019 Apr; 68(8):1311-1319. PubMed ID: 30952158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
    Takeuchi R; Lawpoolsri S; Imwong M; Kobayashi J; Kaewkungwal J; Pukrittayakamee S; Puangsa-art S; Thanyavanich N; Maneeboonyang W; Day NP; Singhasivanon P
    Malar J; 2010 Nov; 9():308. PubMed ID: 21040545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.
    Maneeboonyang W; Lawpoolsri S; Puangsa-Art S; Yimsamran S; Thanyavanich N; Wuthisen P; Prommongkol S; Chaimongkul W; Rukmanee P; Rukmanee N; Chavez IF; Buchachart K; Krudsood S; Singhasivanon P
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):9-18. PubMed ID: 21323159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors.
    Gomes Mdo S; Vieira JL; Machado RL; Nacher M; Stefani A; Musset L; Legrand E; Menezes RA; Júnior AA; Sousa AP; Couto VS; Couto ÁA
    Malar J; 2015 Oct; 14():402. PubMed ID: 26453152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
    Gonzalez-Ceron L; Rodriguez MH; Sandoval MA; Santillan F; Galindo-Virgen S; Betanzos AF; Rosales AF; Palomeque OL
    Malar J; 2015 Oct; 14():426. PubMed ID: 26518132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
    Yadav RS; Ghosh SK
    J Parasitol; 2002 Oct; 88(5):1042-4. PubMed ID: 12435158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.
    Rishikesh K; Kamath A; Hande MH; Vidyasagar S; Acharya RV; Acharya V; Belle J; Shastry AB; Saravu K
    Malar J; 2015 Aug; 14():310. PubMed ID: 26259839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India.
    Saravu K; Kumar R; Ashok H; Kundapura P; Kamath V; Kamath A; Mukhopadhyay C
    PLoS One; 2016; 11(6):e0157666. PubMed ID: 27315280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment.
    Pereira D; Daher A; Zanini G; Maia I; Fonseca L; Pitta L; Ruffato R; Marchesini P; Fontes CJ
    Malar J; 2016 Sep; 15():477. PubMed ID: 27639847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.
    Vijaykadga S; Rojanawatsirivej C; Congpoung K; Wilairatana P; Satimai W; Uaekowitchai C; Pumborplub B; Sittimongkol S; Pinyorattanachote A; Prigchoo P
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):566-9. PubMed ID: 15689067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.
    Buchachart K; Krudsood S; Singhasivanon P; Treeprasertsuk S; Phophak N; Srivilairit S; Chalermrut K; Rattanapong Y; Supeeranuntha L; Wilairatana P; Brittenham G; Looareesuwan S
    Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):720-6. PubMed ID: 12041544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
    Gogtay NJ; Desai S; Kamtekar KD; Kadam VS; Dalvi SS; Kshirsagar NA
    Ann Trop Med Parasitol; 1999 Dec; 93(8):809-12. PubMed ID: 10715673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.
    Yeshiwondim AK; Tekle AH; Dengela DO; Yohannes AM; Teklehaimanot A
    Acta Trop; 2010 Feb; 113(2):105-13. PubMed ID: 19835832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China.
    Qingjun L; Jihui D; Laiyi T; Xiangjun Z; Jun L; Hay A; Shires S; Navaratnam V
    Bull World Health Organ; 1998; 76 Suppl 1(Suppl 1):21-7. PubMed ID: 9763719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
    Pukrittayakamee S; Vanijanonta S; Chantra A; Clemens R; White NJ
    J Infect Dis; 1994 Apr; 169(4):932-5. PubMed ID: 8133114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    Duarte EC; Pang LW; Ribeiro LC; Fontes CJ
    Am J Trop Med Hyg; 2001 Nov; 65(5):471-6. PubMed ID: 11716100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border.
    Höglund R; Moussavi Y; Ruengweerayut R; Cheomung A; Äbelö A; Na-Bangchang K
    Malar J; 2016 Feb; 15():129. PubMed ID: 26928448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan.
    Valibayov A; Abdullayev F; Mammadov S; Gasimov E; Sabatinelli G; Kondrachine AV; Ringwald P
    Acta Trop; 2003 Sep; 88(1):99-102. PubMed ID: 12943984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.